

# Mario Santinami

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1646579/publications.pdf>

Version: 2024-02-01

163  
papers

13,927  
citations

36203

51  
h-index

20900

115  
g-index

170  
all docs

170  
docs citations

170  
times ranked

15444  
citing authors

#	ARTICLE	IF	CITATIONS
1	Genetic Layout of Melanoma Lesions Is Associated with BRAF/MEK-Targeted Therapy Resistance and Transcriptional Profiles. <i>Journal of Investigative Dermatology</i> , 2022, 142, 3030-3040.e5.	0.3	6
2	The role of sentinel node tumor burden in modeling the prognosis of melanoma patients with positive sentinel node biopsy: an Italian melanoma intergroup study (Nâ€™=â€™2,086). <i>BMC Cancer</i> , 2022, 22, .	1.1	5
3	Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis. <i>British Journal of Cancer</i> , 2021, 124, 574-580.	2.9	27
4	Surgical treatment of melanoma metastases to the small bowel: A single cancer referral center real-life experience. <i>European Journal of Surgical Oncology</i> , 2021, 47, 409-415.	0.5	3
5	The role of sentinel lymph node status performed in melanoma patients with local recurrence or in transit metastasis. <i>European Journal of Surgical Oncology</i> , 2021, 47, 1152-1156.	0.5	0
6	Survival in Patients With Sentinel Nodeâ€™Positive Melanoma With Extranodal Extension. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 1165-1173.	2.3	3
7	miR-146a-5p impairs melanoma resistance to kinase inhibitors by targeting COX2 and regulating NFkB-mediated inflammatory mediators. <i>Cell Communication and Signaling</i> , 2020, 18, 156.	2.7	18
8	Clinical applications of receptor-binding radiopharmaceutical 99mTc-Tilmanocept: sentinel node biopsy and beyond. <i>Clinical and Translational Imaging</i> , 2020, 8, 413-418.	1.1	5
9	Reply to E. Hindiâ€™. <i>Journal of Clinical Oncology</i> , 2020, 38, 3238-3240.	0.8	3
10	Timing of sentinel node biopsy independently predicts disease-free and overall survival in clinical stage I-II melanoma patients: A multicentre study of the Italian Melanoma Intergroup (IMI). <i>European Journal of Cancer</i> , 2020, 137, 30-39.	1.3	4
11	Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. <i>New England Journal of Medicine</i> , 2020, 383, 1139-1148.	13.9	256
12	1100P Restricted mean survival time (RMST) and cure-rate modeling in estimating survival benefit with adjuvant dabrafenib (D) plus trametinib (T) treatment in melanoma. <i>Annals of Oncology</i> , 2020, 31, S743-S744.	0.6	0
13	Factors Affecting Sentinel Node Metastasis in Thin (T1) Cutaneous Melanomas: Development and External Validation of a Predictive Nomogram. <i>Journal of Clinical Oncology</i> , 2020, 38, 1591-1601.	0.8	50
14	Systemic Therapy for Melanoma: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2020, 38, 3947-3970.	0.8	190
15	Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 358-372.	5.1	94
16	Analysis of Sentinel Node Biopsy and Clinicopathologic Features as Prognostic Factors in Patients With Atypical Melanocytic Tumors. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1327-1336.	2.3	3
17	An actionable axis linking NFATc2 to EZH2 controls the EMT-like program of melanoma cells. <i>Oncogene</i> , 2019, 38, 4384-4396.	2.6	36
18	Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 701-710.	5.1	50

#	ARTICLE	IF	CITATIONS
19	Reply to E. HindiÃ© and K.R. Hess. Journal of Clinical Oncology, 2019, 37, 1356-1358.	0.8	1
20	Association between baseline disease characteristics and relapse-free survival (RFS) in patients (pts) with BRAF V600-mutant resected stage III melanoma treated with adjuvant dabrafenib (D) + trametinib (T) or placebo (PBO).. Journal of Clinical Oncology, 2019, 37, 9582-9582.	0.8	1
21	Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected <i>BRAF</i> V600â€ˆMutant Stage III Melanoma. Journal of Clinical Oncology, 2018, 36, 3441-3449.	0.8	226
22	Estimate of long-term relapse-free survival (RFS) and analysis of baseline factors associated with RFS in the COMBI-AD trial. Annals of Oncology, 2018, 29, viii445.	0.6	2
23	MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2018, 19, 916-929.	5.1	131
24	Mutational and immune gene expression profiling at relapse in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (pbo) in the COMBI-AD trial.. Journal of Clinical Oncology, 2018, 36, 9574-9574.	0.8	1
25	Effect on health-related quality of life (HRQOL) of adjuvant treatment (tx) with dabrafenib plus trametinib (D + T) in patients (pts) with resected stage III <i>BRAF</i>-mutant melanoma.. Journal of Clinical Oncology, 2018, 36, 9590-9590.	0.8	9
26	Dabrafenib plus trametinib (D + T) as adjuvant treatment of resected <i>BRAF</i>-mutant stage III melanoma: Findings from the COMBI-AD trial analyzed based on AJCC 8 classification.. Journal of Clinical Oncology, 2018, 36, 9591-9591.	0.8	8
27	The inflammation markers in serum of tumor-bearing rats after plasmonic photothermal therapy. , 2018, , .		0
28	Long-Term Survival after Complete Surgical Resection and Adjuvant Immunotherapy for Distant Melanoma Metastases. Annals of Surgical Oncology, 2017, 24, 3991-4000.	0.7	102
29	Melanoma staging: Evidenceâ€ˆbased changes in the American Joint Committee on Cancer eighth edition cancer staging manual. Ca-A Cancer Journal for Clinicians, 2017, 67, 472-492.	157.7	1,662
30	Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma. New England Journal of Medicine, 2017, 377, 1813-1823.	13.9	1,192
31	Sex-specific effect of RNASEL rs486907 and miR-146a rs2910164 polymorphismsâ€™ interaction as a susceptibility factor for melanoma skin cancer. Melanoma Research, 2017, 27, 309-314.	0.6	13
32	Prognostic factors in Merkel cell carcinoma patients undergoing sentinel node biopsy. European Journal of Surgical Oncology, 2017, 43, 1536-1541.	0.5	13
33	microRNA Expression in Sentinel Nodes from Progressing Melanoma Patients Identifies Networks Associated with Dysfunctional Immune Response. Genes, 2016, 7, 124.	1.0	8
34	Immunomodulatory Factors Control the Fate of Melanoma Tumor Initiating Cells. Stem Cells, 2016, 34, 2449-2460.	1.4	21
35	NFATc2 is an intrinsic regulator of melanoma dedifferentiation. Oncogene, 2016, 35, 2862-2872.	2.6	43
36	Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b. Oncotarget, 2016, 7, 4428-4441.	0.8	84

#	ARTICLE	IF	CITATIONS
37	3321 The role of sentinel lymph node biopsy in Merkel Cell Carcinoma: Analysis of 64 patients from a single institution. <i>European Journal of Cancer</i> , 2015, 51, S671.	1.3	0
38	Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 999-1009.	2.0	138
39	Lymph-Node Ratio in Patients with Cutaneous Melanoma: A Multi-Institution Prognostic Study. <i>Annals of Surgical Oncology</i> , 2015, 22, 2127-2134.	0.7	18
40	Factors predictive of pelvic lymph node involvement and outcomes in melanoma patients with metastatic sentinel lymph node of the groin: A multicentre study. <i>European Journal of Surgical Oncology</i> , 2015, 41, 823-829.	0.5	11
41	Differences in Clinicopathological Features and Distribution of Risk Factors in Italian Melanoma Patients. <i>Dermatology</i> , 2015, 230, 256-262.	0.9	6
42	Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study. <i>Annals of Oncology</i> , 2015, 26, 798-803.	0.6	118
43	“Cancer Bio-Immunotherapy in Siena” Eleventh Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 17-19, 2013. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 131-135.	2.0	0
44	ITOC2 “038. Role of exosomes in immune suppression. <i>European Journal of Cancer</i> , 2015, 51, S13.	1.3	3
45	Electrochemotherapy: a good idea in recurrent basal cell carcinoma treatment. <i>Melanoma Management</i> , 2015, 2, 27-31.	0.1	3
46	Armed antibodies for cancer treatment: a promising tool in a changing era. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 113-121.	2.0	28
47	The number of excised lymph nodes is associated with survival of melanoma patients with lymph node metastasis. <i>Annals of Oncology</i> , 2014, 25, 240-246.	0.6	34
48	Enrichment of CD56dimKIR+CD57+ highly cytotoxic NK cells in tumour-infiltrated lymph nodes of melanoma patients. <i>Nature Communications</i> , 2014, 5, 5639.	5.8	109
49	Association of promoter polymorphism $\sim 765$ G<sup>C</sup> in the <sup>PTGS</sup>2 gene with malignant melanoma in <sup>I</sup>alian patients and its correlation to gene expression in dermal fibroblasts. <i>Experimental Dermatology</i> , 2014, 23, 766-768.	1.4	4
50	Number of Excised Lymph Nodes as a Quality Assurance Measure for Lymphadenectomy in Melanoma. <i>JAMA Surgery</i> , 2014, 149, 700.	2.2	42
51	Transcriptional Profiling of Melanoma Sentinel Nodes Identify Patients with Poor Outcome and Reveal an Association of CD30+ T Lymphocytes with Progression. <i>Cancer Research</i> , 2014, 74, 130-140.	0.4	27
52	Accuracy and prognostic value of sentinel lymph node biopsy in head and neck melanomas. <i>Journal of Surgical Research</i> , 2014, 187, 518-524.	0.8	28
53	Alternative Activation of Human Plasmacytoid DCs In Vitro and in Melanoma Lesions: Involvement of LAG-3. <i>Journal of Investigative Dermatology</i> , 2014, 134, 1893-1902.	0.3	74
54	Prediction of Survival in Patients With Thin Melanoma: Results From a Multi-Institution Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 2479-2485.	0.8	103

#	ARTICLE	IF	CITATIONS
55	Nonsentinel Lymph Node Status in Patients With Cutaneous Melanoma: Results From a Multi-Institution Prognostic Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 935-941.	0.8	49
56	Enrichment of KIR+CD57+ highly cytotoxic NK cells in sentinel lymph nodes of melanoma patients. <i>Journal of Translational Medicine</i> , 2014, 12, P10.	1.8	0
57	Cutaneous Melanoma in Children and Adolescents: The Italian Rare Tumors in Pediatric Age Project Experience. <i>Journal of Pediatrics</i> , 2014, 164, 376-382.e2.	0.9	47
58	A phase II study of intratumoral application of L191L2/L19TNF in melanoma patients in clinical stage III or stage IV M1a with presence of injectable cutaneous and/or subcutaneous lesions.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS9103-TPS9103.	0.8	4
59	Isolated limb perfusion with the tumor-targeting human monoclonal antibody-cytokine fusion protein L19-TNF plus melphalan and mild hyperthermia in patients with locally advanced extremity melanoma. <i>Journal of Surgical Oncology</i> , 2013, 107, 173-179.	0.8	72
60	Analysis of surrogate gene expression markers in peripheral blood of melanoma patients to predict treatment outcome of adjuvant pegylated interferon alpha 2b (EORTC 18991 side study). <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 1223-1233.	2.0	5
61	Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell response. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 897-908.	2.0	31
62	The use of polytetrafluoroethylene to facilitate the vascular access in recurrent melanoma to limbs. <i>International Journal of Surgery Case Reports</i> , 2013, 4, 40-43.	0.2	1
63	A variant in FTO shows association with melanoma risk not due to BMI. <i>Nature Genetics</i> , 2013, 45, 428-432.	9.4	111
64	Biological insights into BRAF <sup>V600</sup> mutations in melanoma patient. <i>Oncolmmunology</i> , 2013, 2, e25594.	2.1	6
65	Clinical and immunologic responses in melanoma patients vaccinated with MAGE-3 genetically modified lymphocytes. <i>International Journal of Cancer</i> , 2013, 132, 2557-2566.	2.3	20
66	CDKN2A and MC1R variants influence dermoscopic and confocal features of benign melanocytic lesions in multiple melanoma patients. <i>Experimental Dermatology</i> , 2013, 22, 411-416.	1.4	26
67	Adjuvant Ganglioside GM2-KLH/QS-21 Vaccination Versus Observation After Resection of Primary Tumor > 1.5 mm in Patients With Stage II Melanoma: Results of the EORTC 18961 Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 3831-3837.	0.8	88
68	Long-Term Results of the Randomized Phase III Trial EORTC 18991 of Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 3810-3818.	0.8	254
69	Modulation of Microenvironment Acidity Reverses Anergy in Human and Murine Tumor-Infiltrating T Lymphocytes. <i>Cancer Research</i> , 2012, 72, 2746-2756.	0.4	470
70	Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I Modified Peptides. <i>Clinical Cancer Research</i> , 2012, 18, 6485-6496.	3.2	61
71	Ulceration and stage are predictive of interferon efficacy in melanoma: Results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. <i>European Journal of Cancer</i> , 2012, 48, 218-225.	1.3	182
72	Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. <i>Lancet Oncology</i> , The, 2012, 13, 879-886.	5.1	273

#	ARTICLE	IF	CITATIONS
73	Small Nodular Melanoma: The Beginning of a Life-Threatening Lesion. A Clinical Study on 11 Cases. <i>Tumori</i> , 2011, 97, 35-38.	0.6	9
74	EORTC 18991 phase III trial: Long-term adjuvant pegylated interferon- $\beta$ (PEG-IFN) versus observation in resected stage III melanoma: Long-term results at 7.6-years follow-up.. <i>Journal of Clinical Oncology</i> , 2011, 29, 8506b-8506b.	0.8	13
75	A phase II study combining ipilimumab and fotemustine in patients with metastatic melanoma: The NIBIT-M1 trial.. <i>Journal of Clinical Oncology</i> , 2011, 29, TPS230-TPS230.	0.8	5
76	Pure Desmoplastic Melanoma. <i>Annals of Surgery</i> , 2010, 252, 1052-1057.	2.1	49
77	pH-dependent antitumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidity. <i>International Journal of Cancer</i> , 2010, 127, 207-219.	2.3	237
78	Phase III Trial Comparing Adjuvant Treatment With Pegylated Interferon Alfa-2b Versus Observation: Prognostic Significance of Autoantibodiesâ€”EORTC 18991. <i>Journal of Clinical Oncology</i> , 2010, 28, 2460-2466.	0.8	69
79	Tumor-Reactive CD8+ Early Effector T Cells Identified at Tumor Site in Primary and Metastatic Melanoma. <i>Cancer Research</i> , 2010, 70, 8378-8387.	0.4	52
80	Heterogeneous Phenotype of Human Melanoma Cells with In Vitro and In Vivo Features of Tumor-Initiating Cells. <i>Journal of Investigative Dermatology</i> , 2010, 130, 1877-1886.	0.3	77
81	Response to Griewank and Bastian. <i>Journal of Investigative Dermatology</i> , 2010, 130, 2331-2332.	0.3	0
82	High Levels of Exosomes Expressing CD63 and Caveolin-1 in Plasma of Melanoma Patients. <i>PLoS ONE</i> , 2009, 4, e5219.	1.1	806
83	Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma: A Phase III Randomized Controlled Trial of Health-Related Quality of Life and Symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group. <i>Journal of Clinical Oncology</i> , 2009, 27, 2916-2923.	0.8	119
84	Impaired STAT Phosphorylation in T Cells from Melanoma Patients in Response to IL-2: Association with Clinical Stage. <i>Clinical Cancer Research</i> , 2009, 15, 4085-4094.	3.2	29
85	Modified peptides in anti-cancer vaccines: are we eventually improving anti-tumour immunity?. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 1159-1167.	2.0	21
86	Cutaneous Melanoma in Childhood and Adolescence Shows Frequent Loss of INK4A and Gain of KIT. <i>Journal of Investigative Dermatology</i> , 2009, 129, 1759-1768.	0.3	54
87	New common variants affecting susceptibility to basal cell carcinoma. <i>Nature Genetics</i> , 2009, 41, 909-914.	9.4	303
88	Single-Institution Series of Early-Stage Merkel Cell Carcinoma: Long-Term Outcomes in 95 Patients Managed with Surgery Alone. <i>Annals of Surgical Oncology</i> , 2009, 16, 2985-2993.	0.7	50
89	Circulating melanoma cells and distant metastasis-free survival in stage III melanoma patients with or without adjuvant interferon treatment (EORTC 18991 side study). <i>European Journal of Cancer</i> , 2009, 45, 3189-3197.	1.3	48
90	Radical dissection after positive groin sentinel biopsy in melanoma patients: rate of further positive nodes. <i>Melanoma Research</i> , 2009, 19, 112-118.	0.6	24

#	ARTICLE	IF	CITATIONS
91	Banked venous homograft replacement of the inferior vena cava for primary leiomyosarcoma. <i>European Journal of Surgical Oncology</i> , 2008, 34, 720-724.	0.5	18
92	Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. <i>Lancet</i> , The, 2008, 372, 117-126.	6.3	620
93	Metamorphosis of melanoma. Trends in size and thickness of cutaneous melanoma over one decade at the Istituto Nazionale Tumori, Milan. <i>Tumori</i> , 2008, 94, 11-13.	0.6	22
94	Adjuvant multi-peptide vaccination in high-risk early melanoma patients. <i>Journal of Clinical Oncology</i> , 2008, 26, 3014-3014.	0.8	3
95	Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. <i>Annals of Oncology</i> , 2007, 18, 226-232.	0.6	252
96	Melanoma immunology: past, present and future. <i>Current Opinion in Oncology</i> , 2007, 19, 121-127.	1.1	57
97	INV 4 Impaired response to ??c cytokines in T cells from melanoma patients. <i>Melanoma Research</i> , 2007, 17, A2.	0.6	0
98	Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. <i>European Journal of Cancer</i> , 2007, 43, 935-946.	1.3	523
99	Multispectral imaging and artificial neural network: mimicking the management decision of the clinician facing pigmented skin lesions. <i>Physics in Medicine and Biology</i> , 2007, 52, 2599-2613.	1.6	58
100	Detection of mutated BRAFV600E variant in circulating DNA of stage III-IV melanoma patients. <i>International Journal of Cancer</i> , 2007, 120, 2439-2444.	2.3	76
101	Advanced Extremity Soft Tissue Sarcoma: Prognostic Effect of Isolated Limb Perfusion in a Series of 88 Patients Treated at a Single Institution. <i>Annals of Surgical Oncology</i> , 2007, 14, 553-559.	0.7	61
102	EORTC 18991: Long-term adjuvant pegylated interferon-alpha2b (PEG-IFN) compared to observation in resected stage III melanoma, final results of a randomized phase III trial. <i>Journal of Clinical Oncology</i> , 2007, 25, 8504-8504.	0.8	18
103	CD133 POSTIVE CELLULAR POPULATION IN HUMAN MELANOMA. <i>FASEB Journal</i> , 2007, 21, A32.	0.2	0
104	Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients and modulation by GM-CSF-based anti-tumor vaccine. <i>Journal of Clinical Oncology</i> , 2007, 25, 21082-21082.	0.8	1
105	Micro-melanoma detection: a clinical study on 206 consecutive cases of pigmented skin lesions with a diameter <math>\leq 3\text{ mm}</math>. <i>British Journal of Dermatology</i> , 2006, 155, 570-573.	1.4	66
106	A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon- $\gamma$ in metastatic melanoma patients. <i>Cancer Immunology, Immunotherapy</i> , 2006, 55, 958-968.	2.0	134
107	Sentinel and Nonsentinel Node Status in Stage IB and II Melanoma Patients: Two-Step Prognostic Indicators of Survival. <i>Journal of Clinical Oncology</i> , 2006, 24, 4464-4471.	0.8	132
108	Vaccination: role in metastatic melanoma. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 1305-1318.	1.1	22



#	ARTICLE	IF	CITATIONS
109	Immunization of Stage IV Melanoma Patients with Melan-A/MART-1 and gp100 Peptides plus IFN- $\gamma$ Results in the Activation of Specific CD8+ T Cells and Monocyte/Dendritic Cell Precursors. <i>Cancer Research</i> , 2006, 66, 4943-4951.	0.4	108
110	Hyperthermic isolation limb perfusion with TNF $\alpha$ in the treatment of in-transit melanoma metastasis. <i>In Vivo</i> , 2006, 20, 739-42.	0.6	6
111	Evaluation of Myeloid Suppressive Cells in Peripheral Blood of Melanoma Patients and Their Modulation by A Heat-shock Protein (HSP)-96 and GM-CSF-based Vaccine. <i>Journal of Immunotherapy</i> , 2005, 28, 659.	1.2	0
112	Does Melanoma Behave Differently in Younger Children Than in Adults? A Retrospective Study of 33 Cases of Childhood Melanoma From a Single Institution. <i>Pediatrics</i> , 2005, 115, 649-654.	1.0	215
113	Automated segmentation of pigmented skin lesions in multispectral imaging. <i>Physics in Medicine and Biology</i> , 2005, 50, N345-N357.	1.6	17
114	Constitutive Expression and Costimulatory Function of LIGHT/TNFSF14 on Human Melanoma Cells and Melanoma-Derived Microvesicles. <i>Cancer Research</i> , 2005, 65, 3428-3436.	0.4	53
115	Narrower Surgical Margins Might be Sufficient in Invasive Horizontal Growth Phase Melanoma. <i>Tumori</i> , 2004, 90, 464-466.	0.6	0
116	Heat Shock Proteins and Their Use as Anticancer Vaccines. <i>Clinical Cancer Research</i> , 2004, 10, 8142-8146.	3.2	62
117	Atypical pleomorphic epithelioid angiomylipoma localized to the pelvis: a case report and review of the literature. <i>Histopathology</i> , 2004, 44, 292-295.	1.6	17
118	Retroperitoneal soft tissue sarcomas. <i>Cancer</i> , 2004, 100, 2448-2455.	2.0	167
119	Immunotherapy of melanoma. <i>Seminars in Cancer Biology</i> , 2003, 13, 391-400.	4.3	48
120	World Health Organization experience in the treatment of melanoma. <i>Surgical Clinics of North America</i> , 2003, 83, 405-416.	0.5	17
121	Chordoma: Natural History and Results in 28 Patients Treated at a Single Institution. <i>Annals of Surgical Oncology</i> , 2003, 10, 291-296.	0.7	204
122	Quality of Surgery and Outcome in Extra-Abdominal Aggressive Fibromatosis: A Series of Patients Surgically Treated at a Single Institution. <i>Journal of Clinical Oncology</i> , 2003, 21, 1390-1397.	0.8	326
123	Hypoxic pelvic and limb perfusion with melphalan and mitomycin C for recurrent limb melanoma. <i>Melanoma Research</i> , 2003, 13, 51-58.	0.6	21
124	E-cadherin Expression on Fine Needle Aspiration Biopsies of Breast Invasive Ductal Carcinomas and Its Relationship to Clinicopathologic Factors. <i>Acta Cytologica</i> , 2003, 47, 363-367.	0.7	8
125	Surgical management of primary melanoma. , 2003, , 247-254.		0
126	Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma. <i>Cancer Research</i> , 2003, 63, 2535-45.	0.4	142



#	ARTICLE	IF	CITATIONS
127	Deliberate hypoxic pelvic and limb chemoperfusion in the treatment of recurrent melanoma. <i>American Journal of Surgery</i> , 2002, 183, 28-36.	0.9	25
128	DNA fragmentation and cell proliferation correlated with tumor grade in patients with hepatocellular carcinoma. <i>Cancer</i> , 2002, 96, 301-305.	2.0	9
129	Clinical and dermatoscopic diagnosis of small pigmented skin lesions. <i>European Journal of Dermatology</i> , 2002, 12, 573-6.	0.3	12
130	Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial. <i>Lancet, The</i> , 2001, 358, 866-869.	6.3	248
131	Impact of Clinical Trials on the Treatment of Melanoma. <i>Surgical Oncology Clinics of North America</i> , 2001, 10, 935-947.	0.6	13
132	Isolated Limb Perfusion. <i>Surgical Oncology Clinics of North America</i> , 2001, 10, 821-832.	0.6	38
133	Sentinel Lymph Node Biopsy in Cutaneous Melanoma: The WHO Melanoma Program Experience. <i>Annals of Surgical Oncology</i> , 2000, 7, 469-474.	0.7	318
134	Sentinel Node Biopsy and Selective Lymph Node Dissection in Cutaneous Melanoma Patients. , 2000, , 235-242.		9
135	Hyperthermic Antitumor Perfusion with Alpha Tumor Necrosis Factor and Doxorubicin for the Treatment of Soft Tissue Limb Sarcoma in Candidates for Amputation. <i>Journal of Immunotherapy</i> , 1999, 22, 407-414.	1.2	24
136	Dissection of regional lymph nodes in cutaneous melanoma. <i>Lancet, The</i> , 1998, 351, 1885.	6.3	0
137	Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. <i>Lancet, The</i> , 1998, 351, 793-796.	6.3	625
138	Treatment of Recurrent Sarcoma of the Extremities by Isolated Limb Perfusion Using Tumor Necrosis Factor Alpha and Melphalan. <i>Tumori</i> , 1996, 82, 579-584.	0.6	25
139	Isolated Pelvic Perfusion for the Treatment of Unresectable Primary or Recurrent Rectal Cancer. <i>Tumori</i> , 1996, 82, 459-462.	0.6	8
140	Intraperitoneal hyperthermic perfusion (IPHP). <i>Oncology Reports</i> , 1996, 3, 1103-6.	1.2	5
141	Current results of pelvic perfusion for non-resectable relapsing of pelvic cancer. <i>Oncology Reports</i> , 1996, 3, 1097-1102.	1.2	0
142	Isolation perfusion in extracorporeal circulation with interleukin-2 and lymphokine-activated killer cells in the treatment of in-transit metastases from limb cutaneous melanoma. <i>Annals of Surgical Oncology</i> , 1995, 2, 61-70.	0.7	14
143	Cardiac and Pulmonary Effects of Alpha Tumor Necrosis Factor Administered by Isolation Perfusion. <i>Tumori</i> , 1995, 81, 197-200.	0.6	2
144	Treatment of primary or relapsing limb cancer by isolation perfusion with high-dose alpha-tumor necrosis factor, gamma-interferon, and melphalan. <i>Cancer</i> , 1994, 73, 483-492.	2.0	75

#	ARTICLE	IF	CITATIONS
145	Hyperthermic antitlastic perfusion in the treatment of stage IIIA-IIIAB melanoma patients. Comparison of two experiences. <i>Melanoma Research</i> , 1994, 4, 269.	0.6	3
146	Excision of primary melanoma. <i>Melanoma Research</i> , 1993, 3, 13.	0.6	4
147	The role of tamoxifen (T) in association with chemotherapy in metastatic melanoma (MM). <i>Melanoma Research</i> , 1993, 3, 53.	0.6	0
148	Adoptive Immunotherapy of Melanoma with Interleukin-2 and Lymphocytes. , 1993, , 243-252.		0
149	Treatment of recurrent in transit metastases from cutaneous melanoma by isolation perfusion in extracorporeal circulation with interleukin-2 and lymphokine activated killer cells. A pilot study. <i>Melanoma Research</i> , 1992, 2, 263-272.	0.6	10
150	Elective lymph node dissection for melanoma: Two perspectives. <i>World Journal of Surgery</i> , 1992, 16, 203-213.	0.8	40
151	Antitumor activity of hyperthermia alone or in combination with cisplatin and melphalan in primary cultures of human malignant melanoma. <i>International Journal of Cell Cloning</i> , 1989, 7, 385-394.	1.6	17
152	Management of nodal metastases from head and neck melanoma. <i>Journal of Surgical Oncology</i> , 1989, 42, 47-53.	0.8	7
153	Seven years experience with hyperthermic perfusions in extracorporeal circulation for melanoma of the extremities. <i>Journal of Surgical Oncology</i> , 1989, 42, 201-208.	0.8	47
154	Clinical status of diagnosis and therapy of malignant melanoma. <i>International Journal of Radiation Applications and Instrumentation Part B, Nuclear Medicine and Biology</i> , 1989, 16, 621-624.	0.3	1
155	Isolation perfusion of the lower limb with platinum. <i>World Journal of Surgery</i> , 1988, 12, 307-309.	0.8	10
156	HLA Antigens in Familial and Sporadic Cutaneous Melanoma. <i>Tumori</i> , 1988, 74, 657-664.	0.6	2
157	Intra-arterial infusion and perfusion chemotherapy for soft tissue sarcomas of the extremities. <i>Cancer Treatment and Research</i> , 1986, , 103-129.	0.2	5
158	Limb-Salvage Procedure in Two Patients with Spindle Cell Carcinoma of the Lower Extremities using Isolation Perfusion. <i>Tumori</i> , 1985, 71, 271-275.	0.6	4
159	Hyperthermic Antitlastic Perfusion in the Treatment of Cancer of the Extremities. <i>Tumori</i> , 1985, 71, 355-359.	0.6	25
160	Prognosis of skin melanoma with regional node metastases (stage II). <i>Journal of Surgical Oncology</i> , 1984, 25, 240-247.	0.8	83
161	Regional Perfusion at High Temperature in Treatment of Stage IIIA-IIIAB Melanoma Patients. <i>Tumori</i> , 1983, 69, 585-588.	0.6	20
162	The advent of minimally invasive lymphadenectomy in melanoma. <i>Annals of Laparoscopic and Endoscopic Surgery</i> , 0, 2, 122-122.	0.5	1

#	ARTICLE	IF	CITATIONS
163	Cutaneous Melanoma - Surgical Treatment. , 0, , .		0